Literature DB >> 20486278

Formation of the cytotoxic aldehyde acrolein during in vitro degradation of cyclophosphamide.

R A Alarcon, J Meienhofer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 20486278     DOI： 10.1038/newbio233250b0

Source DB:  PubMed          Journal:  Nat New Biol        ISSN： 0090-0028


× No keyword cloud information.
  10 in total

1.  In vitro binding of 3H-acrolein to regeneration rat liver DNA polymerase.

Authors:  N Munsch; A M de Recondo; C Frayssinet
Journal:  Experientia       Date:  1974-11-15

2.  Formation of 4-ketocyclophosphamide by the oxidation of cyclophosphamide with KMnO4.

Authors:  M Jarman
Journal:  Experientia       Date:  1973

3.  Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.

Authors:  Fei Li; Andrew D Patterson; Constance C Höfer; Kristopher W Krausz; Frank J Gonzalez; Jeffrey R Idle
Journal:  Biochem Pharmacol       Date:  2010-06-10       Impact factor: 5.858

4.  Lymphocyte deactivation by (potential immunosuppressant) alkylating metabolites of cyclophosphamide.

Authors:  M W Whitehouse; F W Beck; M M Dröge; R F Struck
Journal:  Agents Actions       Date:  1974-04

5.  Ultrastructural autoradiographic study of the intracellular fixation of 3H-acrolein.

Authors:  F Marano; M Demestère
Journal:  Experientia       Date:  1976-04-15

6.  [Relationship between Chemical Constitution and Theraeutic Activity of alpha, beta-unsaturated Aldehydes in the Ehrlich-Solid-Tumor of the Mouse].

Authors:  H Zollner; H Esterbauer; E Schauenstein
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1975

7.  Cyclophosphamide-impaired regulation of hepatic heme metabolism.

Authors:  M Rizzardini; A Ferraroli; D Dal Fiume; L Cantoni
Journal:  Experientia       Date:  1984-12-15

8.  Does acrolein contribute to the cytotoxicity of cyclophosphamide?

Authors:  E Wrabetz; G Peter; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

9.  Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.

Authors:  Francesco Patti; Salvatore Lo Fermo
Journal:  Autoimmune Dis       Date:  2011-03-15

Review 10.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.